Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Buy” by Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $131.86.

A number of research firms have recently issued reports on LNTH. Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities lowered their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st.

Lantheus Trading Down 1.3 %

LNTH opened at $94.65 on Tuesday. The stock’s fifty day simple moving average is $90.39 and its 200 day simple moving average is $99.69. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The stock has a market cap of $6.58 billion, a PE ratio of 15.75 and a beta of 0.46.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the third quarter worth about $25,000. Signaturefd LLC boosted its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. bought a new position in Lantheus in the third quarter valued at approximately $51,000. Finally, GAMMA Investing LLC lifted its stake in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.